Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:DHC
NasdaqGS:DHCHealth Care REITs

A Look At Diversified Healthcare Trust (DHC) Valuation After Earnings Reveal Narrower Net Loss

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

Assessing Mercury Systems (MRCY) Valuation After Growth Update And Rising Defense Opportunities

Mercury Systems (MRCY) recently reported year over year growth in bookings, revenue, adjusted EBITDA, and backlog, supported by faster customer deliveries and factory automation investments, and outlined new opportunities linked to the defense budget. See our latest analysis for Mercury Systems. At a share price of US$89.03, Mercury Systems has seen a 33.28% 90 day share price return and a very large 100.47% 1 year total shareholder return, suggesting recent momentum has been strong as...
NasdaqGS:ADSK
NasdaqGS:ADSKSoftware

Autodesk’s BioDapt Partnership Puts AI Prosthetics In Investor Focus

Autodesk and BioDapt are partnering to develop high performance prosthetics for para athletes using Autodesk's AI powered Fusion platform. The collaboration focuses on optimizing design and scaling production of advanced prosthetic limbs ahead of major global sporting events. The project highlights a new application of Autodesk's design and cloud tools in assistive technology and elite para sports. Autodesk (NasdaqGS:ADSK), recently trading at around $245.87, is best known for its software...
NYSE:MUSA
NYSE:MUSASpecialty Retail

Assessing Murphy USA (MUSA) Valuation After Insider Sales And Mixed Analyst Reactions

Murphy USA (MUSA) has drawn fresh attention after a cluster of insider stock sales by senior leaders, including its fuels chief and a board director, following recent mixed analyst commentary on the retailer’s latest quarterly update. See our latest analysis for Murphy USA. The recent insider selling comes as Murphy USA’s share price, at US$390.74, shows mixed momentum, with a 30 day share price return of a 7.5% decline, a 3 year total shareholder return of 51.96% and a 5 year total...
NYSE:OWL
NYSE:OWLCapital Markets

Blue Owl Capital (OWL) Valuation Check As Private Wealth Growth And 2026 Dividend Guidance Shape Expectations

What the new shelf registration could mean for Blue Owl Capital Blue Owl Capital (OWL) recently filed a US$615.5 million shelf registration for up to 50,000,000 Class A shares tied to an ESOP related offering, adding a fresh wrinkle to its income focused story. This move arrives alongside management’s commitment to a fixed US$0.92 annual dividend for 2026 and strong demand for its private wealth products, including a 66% year over year increase in dedicated offerings targeting individual...
NasdaqGS:BSY
NasdaqGS:BSYSoftware

A Look At Bentley Systems (BSY) Valuation After Earnings Beat And Upgraded 2026 Guidance

Bentley Systems (BSY) is back on investors’ radar after its fourth quarter and full year 2025 results beat revenue expectations, and management issued 2026 guidance that came in above prior analyst forecasts. See our latest analysis for Bentley Systems. Even after a strong post earnings bounce, Bentley Systems’ latest share price of US$36.55 still reflects a 12.7% 90 day share price decline and a 16.2% 1 year total shareholder return decline. As a result, the recent 8% 7 day share price gain...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Assessing Vera Therapeutics (VERA) Valuation After FDA Priority Review And Phase 3 IgAN Success

Vera Therapeutics (VERA) is back in focus after the FDA granted priority review to its lead drug candidate, atacicept, following positive Phase 3 IgA nephropathy data and company updates on funding and launch readiness. See our latest analysis for Vera Therapeutics. Despite the FDA priority review and Phase 3 success for atacicept, Vera Therapeutics’ recent share price returns have cooled, with a 30 day share price return decline of 5.71% and a year to date share price return decline of...
ASX:HVN
ASX:HVNMultiline Retail

A Look At Harvey Norman Holdings (ASX:HVN) Valuation After Its Half Year Earnings And Higher Dividend

Harvey Norman Holdings (ASX:HVN) has drawn fresh attention after releasing its half year 2025 results along with a higher fully franked interim dividend of A$0.145 per share, with the stock falling 8% on the day. See our latest analysis for Harvey Norman Holdings. At a share price of A$5.76, Harvey Norman’s 1 day share price return of a 9.0% decline and 30 day share price return of an 11.11% decline contrast with a 1 year total shareholder return of 15.21% and 3 year total shareholder return...
SGX:C09
SGX:C09Real Estate

Assessing City Developments (SGX:C09) Valuation After Strong 2025 Earnings And New Dividend Announcement

Earnings and dividend move City Developments into focus City Developments (SGX:C09) has drawn fresh attention after releasing its full year 2025 results, alongside declaring an annual dividend of S$0.2500 per share payable in May 2026. See our latest analysis for City Developments. The strong full year 2025 results and new S$0.2500 dividend have arrived alongside a 36.39% 90 day share price return and a 1 year total shareholder return of 95.83%. This suggests momentum has been building from...
OB:AKRBP
OB:AKRBPOil and Gas

Aker BP’s AI‑Enabled MMO Alliance With Aker Solutions Might Change The Case For Investing In Aker BP (OB:AKRBP)

In February 2026, Aker Solutions announced it had secured a five-year Maintenance, Modification and Operation services agreement from Aker BP, covering all Aker BP-operated assets on the Norwegian continental shelf from 1 March 2026, with options for two additional four-year extensions. This next-generation MMO alliance stands out for its use of fully integrated teams, data-driven and AI-supported workflows, and performance‑linked commercial incentives to modernise Aker BP’s facilities and...
NYSE:PNFP
NYSE:PNFPBanks

Pinnacle Financial Partners (PNFP) Is Down 10.1% After Inflation, Credit Worries Hit Regional Banks – Has The Bull Case Changed?

In late February 2026, Pinnacle Financial Partners was highlighted by hedge funds as one of the ten leading banking stocks, with analysts citing stronger capital levels and higher earnings forecasts following its fourth-quarter results and management’s confident outlook. A few days later, hotter-than-expected inflation data and rising worries about credit risk in areas like private credit and leveraged loans led investors to reassess regional banks’ risk profiles, putting pressure on...
NYSE:FOUR
NYSE:FOURDiversified Financial

A Look At Shift4 Payments (FOUR) Valuation After Weak Guidance And Leadership Change

Shift4 Payments (FOUR) is back in focus after a sharp post earnings sell off, weaker forward guidance, and the resignation of Executive Chairman Jared Isaacman. Shares have slid to multi year lows despite ongoing international expansion. See our latest analysis for Shift4 Payments. The weak outlook and leadership change have come on top of a sharp reset in expectations, with a 1 day share price return of 9.0% decline and a 1 year total shareholder return of 55.4% decline, pointing to fading...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

How Robust 2026 Guidance And Backlog Conversion At Sterling Infrastructure (STRL) Has Changed Its Investment Story

Sterling Infrastructure, Inc. has already reported its fourth-quarter and full-year 2025 results, with Q4 sales of US$755.61 million versus US$498.83 million a year earlier, and full-year 2025 sales of US$2.49 billion and net income of US$290.15 million. Alongside these results, management issued 2026 guidance calling for US$3.05–3.20 billion in revenue and US$11.65–12.25 in diluted EPS, signaling confidence in converting a much larger backlog and recent acquisitions into earnings. We will...
NasdaqCM:SLNO
NasdaqCM:SLNOBiotechs

How Profitability from VYKAT XR and a New CFO Will Impact Soleno Therapeutics (SLNO) Investors

Soleno Therapeutics recently reported that its fourth-quarter 2025 results marked a shift to profitability, with net income of US$43.36 million and full-year net income of US$20.89 million, driven by the commercial launch of VYKAT XR for hyperphagia in Prader-Willi syndrome. The company also announced that long-time finance leader James Mackaness will retire and be succeeded by experienced biopharma and healthcare executive Jennifer Fulk as Chief Financial Officer, reinforcing its move from...
ASX:APZ
ASX:APZREITs

Aspen Group (ASX:APZ) Is Up 8.1% After Lifting Revenue And Clarifying 2026 Dividend Guidance – Has The Bull Case Changed?

In February 2026, Aspen Group reported half-year results to 31 December 2025, with revenue rising to A$69.97 million and net income to A$35.94 million, and issued dividend guidance of 11.0 cents for fiscal 2026. The modest uplift in earnings per share, alongside clearer dividend guidance, offers investors a more defined picture of Aspen Group’s capital returns profile. We’ll now explore how Aspen Group’s increased revenue and clarified 2026 dividend guidance shape the company’s broader...
NYSE:BORR
NYSE:BORREnergy Services

What Borr Drilling (BORR)'s Q4 Loss and New Rig Contracts Means For Shareholders

In February 2026, Borr Drilling reported fourth-quarter 2025 revenue of US$259.4 million and a net loss of US$1.0 million, alongside new and extended jack-up rig contracts across Mexico, Brunei, the U.S., Gabon, Congo, and offshore Germany that enhance fleet utilization and revenue visibility. An interesting angle is how this mix of lower quarterly profitability but fuller rig calendars could reshape views on Borr Drilling’s risk profile and earnings quality. Next, we’ll examine how these...
NYSE:BSM
NYSE:BSMOil and Gas

Assessing Black Stone Minerals (BSM) Valuation After Strong 2025 Results And New 2026 Production Guidance

Why Black Stone Minerals Is In Focus After Its Latest Earnings Release Black Stone Minerals (BSM) is back on investors’ radar after releasing fourth quarter and full year 2025 results that highlighted higher revenue and net income, alongside fresh 2026 production guidance and detailed 2025 operating metrics. See our latest analysis for Black Stone Minerals. The earnings release and 2026 production guidance arrived after a steady run, with Black Stone Minerals’ share price showing an 11.77%...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-2359 Clinical Data Update

Why the latest MRT-2359 data matters for Monte Rosa Therapeutics (GLUE) Monte Rosa Therapeutics (GLUE) is back on investors’ radar after updated clinical data for its MRT-2359 prostate cancer program, presented at the ASCO GU Symposium, supported a move into Phase 2 and potential registrational studies. See our latest analysis for Monte Rosa Therapeutics. Despite the positive MRT-2359 update and upcoming conference appearance, Monte Rosa Therapeutics’ recent momentum has cooled. The company...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX?

TG Therapeutics recently reported fourth-quarter 2025 results showing revenue of US$192.57 million, up sharply from US$108.19 million a year earlier, while quarterly net income was essentially flat and earnings per share came in below analyst expectations. For 2025 as a whole, the company recorded US$616.29 million in revenue and a very large increase in net income to US$447.18 million, largely reflecting the growing contribution of BRIUMVI alongside raised guidance for 2026. We’ll now...
NYSE:ARDT
NYSE:ARDTHealthcare

What Ardent Health (ARDT)'s Enterprise AI Virtual Care Rollout Means For Shareholders

In February 2026, Ardent Health announced a partnership with hellocare.ai to roll out an enterprise AI platform for virtual nursing, telehealth, and patient safety monitoring across more than 2,000 inpatient rooms, aiming to enhance clinical capacity and standardize virtual care workflows. This move deepens Ardent’s digital transformation by combining AI-powered monitoring, purpose-built hardware, and clinical integration to create a unified, data-driven virtual care infrastructure that...
NasdaqGS:DRH
NasdaqGS:DRHHotel and Resort REITs

A Look At DiamondRock Hospitality (DRH) Valuation After Earnings Beat And Record Funds From Operations

Earnings beat puts DiamondRock Hospitality (DRH) in focus Fresh off fourth quarter and full year 2025 results that topped Wall Street expectations on funds from operations, DiamondRock Hospitality (DRH) is back on investors’ radar as management outlines its next phase. See our latest analysis for DiamondRock Hospitality. At a share price of US$10.04, DiamondRock Hospitality has seen a 9.37% 1 month share price return and an 11.80% 3 month share price return, while its 1 year total shareholder...
SEHK:6869
SEHK:6869Communications

A Look At Yangtze Optical Fibre And Cable (SEHK:6869) Valuation After MWC Barcelona 2026 Hollow Core Fibre Launch

Yangtze Optical Fibre And Cable Limited (SEHK:6869) is in focus as it showcases new optical connectivity solutions at MWC Barcelona 2026, including a launch event for its hollow core fibre technology. See our latest analysis for Yangtze Optical Fibre And Cable Limited. The MWC Barcelona spotlight comes on the back of a sharp shift in sentiment around Yangtze Optical Fibre And Cable Limited, with a 30 day share price return of 77.78% and a year to date share price return of 183.97%. The very...
NYSE:AHR
NYSE:AHRHealth Care REITs

A Look At American Healthcare REIT (AHR) Valuation After Its Large ATM Equity Raise And 2026 Outlook

American Healthcare REIT (AHR) has come into focus after launching and completing a sizeable at the market equity program, raising hundreds of millions of dollars alongside fresh earnings and 2026 guidance. See our latest analysis for American Healthcare REIT. The new equity program and recent capital raise come after a period of strong interest in American Healthcare REIT. The 30 day share price return is 11.36% and the year to date share price return is 10.58%, while the 1 year total...